Estimating the Net Value of Treating Hepatitis C Virus Using Newly Available Direct-Acting Antivirals in India (Supporting Datasets)

Recently developed direct-acting antiviral (DAA) treatments for hepatitis
C virus (HCV) have been groundbreaking for their high efficacy across
disease genotypes and lack of severe side effects. This study uses a
cost-of-illness (COI) approach to estimate the net value conferred by this
class of drugs using the cost and efficacy of one of these novel drug
combinations, sofosbuvir and velpatasvir (SOF/VEL), recently licensed for
generic manufacture in India. This study considers COI of lifetime
earnings lost by patients and potential secondarily infected individuals
due to disability and premature death from HCV infection. Expected net
benefits of treatment are substantial for non-cirrhotic (NC) and
compensated cirrhotic (CC) patients (ranging from 5,98,003 INR for NC
women to 1,05,25,504 INR for CC men). Increased earnings are not
sufficient to fully offset cost of treatment for decompensated cirrhotic
individuals but treatment may still be justified on the basis of the
intrinsic value of health improvements and other treatment benefits.